Emergent Biosolutions (NYSE:EBS) Releases Quarterly Earnings Results, Beats Estimates By $0.68 EPS

Emergent Biosolutions (NYSE:EBS) posted its earnings results on Wednesday. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.68, FiscalAI reports. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%. The company had revenue of $234.30 million during the quarter, compared to analysts’ expectations of $177.50 million.

Here are the key takeaways from Emergent Biosolutions’ conference call:

• Q2 results exceeded expectations, with revenue of $234 million and adjusted EBITDA of $97 million, up from $33 million a year earlier. Medical countermeasure deliveries to U.S. government customers were accelerated, driving much of the outperformance.
• The medical countermeasures business remains a key growth driver, with Q2 revenue of $168 million and new contract modifications totaling $117.2 million for ACAM2000 and botulism antitoxin. International MCM sales represented about 20% of first-half MCM revenue.
• Emergent lowered 2026 revenue guidance to $645 million-$675 million from $720 million-$760 million and reduced adjusted EBITDA guidance to $130 million-$150 million, citing increased competition, pricing pressure, and volume pressure in the naloxone market.
• The company recorded a $191 million non-cash impairment charge against its NARCAN asset group and expects further price erosion as new nasal naloxone competitors enter the market. Emergent said total naloxone unit demand may remain roughly flat while it works to defend its more-than-50% market share.
• Emergent is restructuring to generate approximately $40 million in annualized savings, including about 90 job reductions, facility closures, and other footprint changes; most savings are expected to be realized in 2027. Liquidity also improved through accounts-receivable collections, debt refinancing, and lower gross debt.

Emergent Biosolutions Trading Down 29.6%

EBS traded down $2.23 during trading on Thursday, reaching $5.31. 3,396,047 shares of the company’s stock were exchanged, compared to its average volume of 863,047. The company has a current ratio of 4.29, a quick ratio of 2.08 and a debt-to-equity ratio of 1.10. Emergent Biosolutions has a one year low of $5.06 and a one year high of $14.06. The firm has a fifty day moving average price of $7.98 and a two-hundred day moving average price of $8.83. The stock has a market capitalization of $274.00 million, a PE ratio of -18.96 and a beta of 2.35.

Insiders Place Their Bets

In related news, SVP Paul Anthony Williams sold 3,000 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total value of $25,200.00. Following the transaction, the senior vice president directly owned 159,098 shares in the company, valued at $1,336,423.20. This trade represents a 1.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of EBS. State Street Corp boosted its stake in Emergent Biosolutions by 10.2% in the fourth quarter. State Street Corp now owns 2,696,375 shares of the biopharmaceutical company’s stock valued at $33,327,000 after acquiring an additional 250,616 shares during the last quarter. Millennium Management LLC lifted its stake in Emergent Biosolutions by 68.9% in the first quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock valued at $12,162,000 after purchasing an additional 1,020,582 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Emergent Biosolutions by 5.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,252,605 shares of the biopharmaceutical company’s stock valued at $27,841,000 after purchasing an additional 112,265 shares during the period. Charles Schwab Investment Management Inc. increased its position in Emergent Biosolutions by 17.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,618,903 shares of the biopharmaceutical company’s stock worth $20,010,000 after buying an additional 237,153 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Emergent Biosolutions by 14.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,132,305 shares of the biopharmaceutical company’s stock valued at $9,987,000 after buying an additional 145,632 shares during the period. Institutional investors own 78.40% of the company’s stock.

Analyst Upgrades and Downgrades

EBS has been the topic of a number of recent analyst reports. Weiss Ratings cut Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Benchmark reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Finally, UBS Group reiterated a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $12.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.